SCHEMBL498897

SCHEMBL498897

c1cc(-c2cccs2)nc(-c2cccs2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 1.00
ALDH1A1 P00352 6/20 1.00
HPGD P15428 4/20 1.00
MAPT P10636 4/20 1.00
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
TDP1 Q9NUW8 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
NPC1 O15118 6/20 0.59
RAB9A P51151 6/20 0.59
HSD17B10 Q99714 3/20 0.59
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12655980 0.88 KDM4E (0.77) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL14538334 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL11563521 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL27645847 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL1573541 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL154819 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL31282814 0.84 KDM4E (0.71) KDM4EALDH1A1HPGDMAPTMEN1
Ammonia Solution, Strong SCHEMBL28220791 0.84 KDM4E (0.71) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL12655942 0.84 KDM4E (0.71) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL27959057 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
US-9226917-B2 Photodynamic therapy for conditions of the eye VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2016-01-05 US disclosed
US-8968715-B2 Drug delivery systems for photodynamic therapy THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-03-03 US disclosed
US-8852629-B2 Drug delivery system for hydrophobic drugs VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2014-10-07 US disclosed
EP-1357912-B9 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-06-13 EP disclosed
EP-1357912-B1 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-04-25 EP disclosed
US-20120041356-A1 PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE QLT INC. (CA) 2012-02-16 US disclosed
US-8106038-B2 Method for reducing or preventing PDT related inflammation QLT INC. (CA) 2012-01-31 US disclosed
US-8034803-B2 Treating an occult choroidal neovascular lesion QLT INC. (CA) 2011-10-11 US disclosed
US-7850981-B2 Immuno-adjuvant PDT treatment of metastatic tumors QLT, INC. (CA) 2010-12-14 US disclosed
US-20030083649-A1 Method for reducing or preventing PDT related inflammation VALEANT SP. Z.O.O. (PL) 2003-05-01 US disclosed
WO-2003028628-A2 PHOTOSENSITIZING CARBAMATE DERIVATIVES MIRAVANT PHARMACEUTICALS, INC. (US) 2003-04-10 WO disclosed
US-20020173832-A1 Reduced fluence rate PDT TECHNOLAS PERFECT VISION GMBH (DE) 2002-11-21 US disclosed
US-20020156062-A1 Drug delivery system for hydrophobic drugs BAUSCH HEALTH COMPANIES INC. (CA) 2002-10-24 US disclosed
US-20020155089-A1 Drug delivery systems for photodynamic therapy UNIVERSITY OF BRITISH COLUMBIA, THE (CA) 2002-10-24 US disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-5045563-A Terthienyl Compound HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1991-09-03 US disclosed
US-4892678-A DOPED WITH AN ANION; SEMICONDUCTOR AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) 1990-01-09 US disclosed
US-4877852-A SEMICONDUCTOR MATERIALS AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1989-10-31 US disclosed
US-4171444-A REACTING A (HETERO-)AROMATIC KETONE, AMMONIA, AND AN ALIPHATIC ALDEHYDE, DEHYDRATING-DEHYDROGENATION CATALYSTS DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156062-A1 Drug delivery system for hydrophobic drugs LIPA, MLEC, ABCG2 KDM4E 3305/4885ALDH1A1 2604/4885HPGD 2568/4885
US-20020155089-A1 Drug delivery systems for photodynamic therapy PIN1, PPOX, DHFR KDM4E 1989/4885ALDH1A1 701/4885HPGD 738/4885
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA KDM4E 3097/4885ALDH1A1 371/4885HPGD 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.